This trial is a prospective, multi-center, randomized controlled clinical study to verify the safety and efficacy of the renal artery radiofrequency ablation system under the guidance of the three-dimensional cardiac electrophysiological mapping system in the application of renal denervation of essential hypertension. Provide the basis for product registration and marketing and clinical application. This trial plans to include 206 subjects, of which 5 are subjects trained and taught by the experimental group leader unit center, and 201 subjects are randomly assigned according to 2:1 (134 cases in the renal artery ablation group and 67 cases in the simple drug treatment group).~Patients will be followed for blood pressure measurement and antihypertensive medication at 7 days, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, and 12 months after the procedure. Patients' urine samples will be collected for drug testing (LC-MS/MS) to determine their medication compliance in an independent laboratory.
To verify the safety and effectiveness of the renal artery radiofrequency ablation system under the guidance of the three-dimensional cardiac electrophysiological mapping system in the renal denervation of essential hypertension.